›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AmoyDx® HANDLE Classic NGS Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amoy DiagnosticsType:
Laboratory Developed Test
Related tests:
1year
Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH (ESMO Asia 2023)
Conclusions CRC-specific HER2 testing protocols and HER2 scoring criteria still needs to be optimised in a more refined and defined manner. HANDLE-based CP40, which combines DNA and RNA in NGS testing, is a potent tool for sensitive and reliable detection of HER2 status in clinical diagnostics.
Next-generation sequencing
|
HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
|
HER-2 overexpression • HER-2 negative
|
PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody • AmoyDx® HANDLE Classic NGS Panel
over2years
Analysis of genomic alterations in pan-cancer from a large real-world Chinese population. (ASCO 2022)
Genomic alterations in real-world Chinese populations have specific characteristics, especially fusion genes. Further characterization of these variants is essential for clinics to guide appropriate targeted therapies.
Real-world evidence • Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RB1 (RB Transcriptional Corepressor 1) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • RET fusion • ALK fusion • RET mutation • ROS1 fusion • RB1 mutation • NRG1 fusion • ALK-ROS1 fusion • NRG1 fusion • NTRK fusion
|
AmoyDx® HANDLE Classic NGS Panel
Share
